Lesley G Mitchell
Overview
Explore the profile of Lesley G Mitchell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Albisetti M, Tartakovsky I, Halton J, Bomgaars L, Chalmers E, Mitchell L, et al.
J Am Heart Assoc
. 2024 Feb;
13(4):e028957.
PMID: 38348778
Background: Congenital heart disease (CHD) is common in children and associated with greater risk of thrombotic complications. Management of these complications with standard-of-care treatment is suboptimal for these children. Methods...
2.
OBrien S, Rodriguez V, Lew G, Newburger J, Schultz C, Orgel E, et al.
Lancet Haematol
. 2023 Nov;
11(1):e27-e37.
PMID: 37980924
Background: Paediatric patients with acute lymphoblastic leukaemia or lymphoma are at increased risk of venous thromboembolism resulting in increased mortality and morbidity. We hypothesised that apixaban, a direct oral anticoagulant,...
3.
Brandao L, Tartakovsky I, Albisetti M, Halton J, Bomgaars L, Chalmers E, et al.
Blood Adv
. 2022 Sep;
6(22):5908-5923.
PMID: 36150047
In the phase 2b/3 DIVERSITY trial, 3 months treatment with dabigatran was noninferior to standard of care (SOC) for acute venous thromboembolism (VTE) in children. In a single-arm, phase 3,...
4.
Mitchell L, Roshammar D, Huang F, Albisetti M, Brandao L, Bomgaars L, et al.
Thromb Haemost
. 2022 Aug;
122(9):1573-1583.
PMID: 35909257
Background: Dabigatran etexilate, a direct oral thrombin inhibitor, is approved to treat venous thromboembolism (VTE) in both adults and children. Objectives: This population analysis characterized relationships between dabigatran total plasma...
5.
Roshammar D, Huang F, Albisetti M, Bomgaars L, Chalmers E, Luciani M, et al.
J Thromb Haemost
. 2021 Feb;
19(5):1259-1270.
PMID: 33636042
Background: Dabigatran etexilate (DE), a direct oral thrombin inhibitor, has been evaluated in children with venous thromboembolism (VTE) using oral solution, pellets, or capsules. Objectives: This study evaluated DE pharmacokinetics...
6.
Halton J, Brandao L, Luciani M, Bomgaars L, Chalmers E, Mitchell L, et al.
Lancet Haematol
. 2020 Dec;
8(1):e22-e33.
PMID: 33290737
Background: Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations of standard of care in children with venous thromboembolism. The aims of this clinical trial were...
7.
Brandao L, Albisetti M, Halton J, Bomgaars L, Chalmers E, Mitchell L, et al.
Blood
. 2019 Dec;
135(7):491-504.
PMID: 31805182
This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children...
8.
OBrien S, Li D, Mitchell L, Hess T, Zee P, Yee D, et al.
Thromb Haemost
. 2019 Mar;
119(5):844-853.
PMID: 30861550
Venous thromboembolic (VTE) complications in children and adolescents with acute lymphoblastic leukaemia (ALL) and T or B cell lymphoblastic lymphoma (T/B cell LL) can result not only in life-threatening acute...
9.
Maas H, Gropper S, Huang F, Stangier J, Tartakovsky I, Brueckmann M, et al.
Thromb Haemost
. 2018 Aug;
118(9):1625-1636.
PMID: 30112751
Background: Physiological age-related changes in the haemostatic and coagulation systems result in differing anticoagulant assay responses to standard anticoagulants. Therefore, we investigated the response of anticoagulant assays to dabigatran etexilate...
10.
Luciani M, Albisetti M, Biss B, Bomgaars L, Brueckmann M, Chalmers E, et al.
Res Pract Thromb Haemost
. 2018 Jul;
2(3):580-590.
PMID: 30046763
Background: Anticoagulant therapy for venous thromboembolism (VTE) in children is largely based on treatment recommendations for adults. However, differences in both physiology (ie, renal maturation and drug excretion) and developmental...